Bottom line
BPC-157 is a peptide: a short chain of 15 amino acids, the building blocks of proteins. It is still being studied and has not been approved as a medicine. Almost all the research on it is animal and lab studies. The reports in people come from a handful of small, short, poorly designed studies. The evidence so far does not show that it heals injuries, treats gut disease, or is safe for routine use in people.38
- Evidence in people
- Limited evidence in people
- Approval status
- BPC-157 is not approved by the FDA (the U.S. government agency that approves medicines). In July 2026, FDA staff reviewed its free-base and acetate-salt forms. The review was for a proposed use: compounded BPC-157 for ulcerative colitis, a bowel disease. Compounding is when a pharmacy makes a custom medicine. Staff concluded that the factors set by law weighed against adding either form to the 503A Bulks List (the FDA's list of ingredients pharmacies may use to make custom medicines).312
- Biggest unknown
- The open question is whether a defined BPC-157 product gives people a meaningful benefit once its harms are counted. Much about it is still poorly understood. That includes whether it works in people. It includes how the body absorbs, spreads, and clears it when taken in the ways most often promoted. It also includes whether the immune system reacts against it, how its effects change with the dose, product quality, and longer-term safety.36
Where research exists
Filled markers show which stages of research this guide covers. They don't rate effectiveness, safety, or study quality.
- Health results in peopleNo useful studies found
- Blood tests and body measurements in peopleCovered in this guide
- Animal studiesCovered in this guide
- Lab studies in cellsCovered in this guide
- Untested idea or marketing claimCovered in this guide
What BPC-157 is
BPC-157 is the common name for a lab-made peptide of 15 amino acids. The FDA's 2026 review noted that published descriptions and marketing have used inconsistent names for it. That can make it hard to tell exactly which material a claim is about.3
BPC-157 free base and BPC-157 acetate salt are two forms of it. They count as different active drug ingredients. Anyone who applies evidence about one form to the other should say so. A label that reads only “BPC-157” may leave it unclear exactly which substance is inside.32
Some descriptions call BPC-157 “gastric juice derived” (from stomach juice). The FDA's review explains that it has reportedly been described as a piece of a larger protein. But the exact protein it would come from has not been identified in people. A story about where a peptide comes from is neither evidence from patients nor a sign of safety.3
Why people are interested
Most of the interest comes from claims about recovery of muscles, tendons, joints and bones, wound repair, inflammatory bowel disease, and protecting tissues. The FDA found compounded BPC-157 products promoted for tendon and ligament injuries, Crohn's disease, celiac disease, and other conditions.3
Cell and animal papers have proposed effects on blood vessel growth, inflammation, and how tissues respond. They have also proposed effects on nitric oxide, a messenger molecule the body uses to send signals. These are proposed explanations for how an effect might come about. They don't show whether a patient would heal faster or function better.38
Marketing claims go far beyond the evidence in people. A proposed way it works gives no grounds for saying BPC-157 treats a named disease or injury in people. The same goes for an animal injury study or a personal story.38
Studies in people
FDA staff found five small, short studies in people. One gave BPC-157 rectally to 24 healthy people. One was an ulcerative colitis study in about 26 people. One was a knee pain report in 17 people. One was a report on interstitial cystitis (a painful bladder condition) in 12 people. The fifth gave it into a vein (IV) to two healthy people.3 What these studies can show depends on how they were designed and reported. It also depends on what they compared BPC-157 with, how long they lasted, and how good their data were. The number of studies alone confirms nothing.
For the proposed ulcerative colitis use, the FDA found the information from people was not enough to tell whether BPC-157 works. Reporting was incomplete. The evidence also lacked the controlled, repeatable results needed to show a benefit. (A controlled study compares people who get a treatment with a similar group who don't.)3
The knee pain report was small and had no comparison group. Some people in it reportedly got BPC-157 together with a thymosin-beta-4 product. That makes it impossible to single out the effect of BPC-157 alone. It also makes it impossible to draw a reliable conclusion about whether it works.38
The FDA found no adequate evidence in people for the promoted tendon-healing uses. It found none for Crohn's disease or celiac disease either. For those uses, benefit in people is unproven.3
The FDA also found an early-stage study listed in a trial registry (a public database of studies). It planned to enroll healthy people. No results had been posted in the material the FDA reviewed. So the registry entry shows only that the research was planned.3
Animal and laboratory studies
A 2025 systematic review (a planned search and summary of the published studies) mapped the research on BPC-157. It found that almost all of it was animal and lab studies. The review helps point out ideas to test and gaps in the research. It cannot turn those findings into proven results in people.8
The animal findings cover different tissues and different kinds of injury. The studies gave the peptide in different ways and in different preparations. They measured different results under different conditions. A positive result in one animal model doesn't show that the same material reaches the right tissue in people. It also doesn't show that it improves pain, function, healing time, or how active a disease is.38
Moving to use in people takes more than repeating an animal experiment. The substance must be clearly described and tested. How much of it reaches the body must be understood. Results that matter to patients must be chosen in advance. And benefits and harms must be compared in properly controlled studies in people.37
Safety
The small studies the FDA reviewed did not appear to report serious harms. That is far from proof of safety. The studies were short and included few people. They gave little detail on safety. They often did not clearly say how people were checked for problems.3
Several ways of taking BPC-157 are often promoted. They include by mouth, by injection under the skin, through the nose, and through the skin. For these, the FDA found no information in people on how the body absorbs, spreads, and clears it. Without data on how much reaches the body, it is hard to link a product to its intended effects or to harm.3
No formal studies were found on whether the immune system reacts against it. As with other peptide products, clumping of the peptide and impurities related to it can affect the risk of an immune reaction. That is a reason to study each product. Whether a given reaction happens is still unknown.36
Unapproved products raise further questions about their identity, strength, purity, and stability. There are also questions about sterility (being free of germs) and formulation (how the product is made up). A lab paper cannot confirm the quality of a product offered to a patient under the same peptide name.34
What the FDA review means
The July 2026 review looked at whether BPC-157 free base and acetate salt should go on the section 503A Bulks List. This was for a proposed use in ulcerative colitis. It was a review about compounding. That is a separate process from approving a new drug.32
FDA staff concluded that the available information weighed against placing both forms on the 503A Bulks List. That information covered the forms' physical and chemical makeup, safety, effectiveness, and past use. That conclusion is based on the law's criteria for compounding and on the evidence the FDA reviewed.3
The Pharmacy Compounding Advisory Committee (PCAC) is a panel that advises the FDA. The FDA does not have to follow its recommendations. A committee discussion approves nothing. A recommendation against putting a substance on the list does not amount to banning the molecule in every setting.512
The FDA's current page on compounding risks lists BPC-157 among substances that may pose significant safety risks. It highlights limited safety information. It also highlights concerns about immune reactions or impurities. The page flags risk. It gives no estimate of how often problems occur. It also cannot replace data from patients on a specific product.4
Questions to ask about a BPC-157 claim
Which substance is being discussed, the free base or the acetate salt? What evidence confirms that the specific product is what it claims to be? What confirms its purity, strength, stability, and sterility?36
Is the claimed benefit backed by a controlled study in people? Did that study use the same substance, given the same way? Did it measure a result patients care about? Or is the claim drawn from cells, animals, personal stories, or a different material?38
What is still unknown about how much reaches the body in people, interactions with other drugs, and immune reactions? What about effects on reproduction or a developing baby, longer-term harm, and how side effects are detected? Is that uncertainty shown as clearly as the proposed benefit?376
How the compounding review works
The July 2026 meeting dealt with a process for compounding that is set by law. This process runs separately from FDA drug approval. It has four steps.
- A substance is nominated
A nomination asks the FDA to consider a raw drug ingredient (a bulk drug substance). It asks whether the ingredient may qualify for a compounding list set by law. Drug approval needs a separate application. - FDA staff assess the record
The FDA looks at what is known about the substance's makeup, past use, effectiveness, and safety. It does this for the use named in the nomination. It then writes a public briefing memo. - PCAC gives advice the FDA doesn't have to follow
The Pharmacy Compounding Advisory Committee discusses the questions and advises the FDA. Its recommendation is only advice. It approves nothing. - The FDA considers final agency action
The FDA weighs the committee's input and finishes its reviews. Only after that does it take any final agency action (its formal, final decision). A meeting or a staff position alone never counts as that final step.
A staff memo is an assessment by FDA staff. An advisory committee recommendation is advice. Neither one is an FDA decision.
References
- 1July 23–24, 2026 Meeting of the Pharmacy Compounding Advisory CommitteeU.S. Food and Drug Administration · 2026-07-23 · FDA document
The meeting record lists the substances proposed for the list and the uses discussed. The committee's votes are advice only. They are not an FDA approval or a final FDA decision.
- 22026 PCAC Voting QuestionsU.S. Food and Drug Administration · 2026-07-23 · FDA document
The questions ask whether the free-base and acetate forms should be placed on the 503A bulks list. Drug approval was outside their scope.
- 3BPC-157 Free Base and Acetate Salt: Pharmacy Compounding Advisory Committee Briefing DocumentU.S. Food and Drug Administration · 2026-07-23 · FDA document
The FDA staff's review of the proposed use for ulcerative colitis, written for the compounding review. The studies in people it found were small, short and too weak to show that it works or is safe.
- 4Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety RisksU.S. Food and Drug Administration · 2026-07-23 · FDA document
FDA's current compounding-risk summary includes BPC-157, KPV, MOTS-c, and the thymosin beta-4 fragment known as TB-500. The listing flags risks and stops well short of a complete safety profile.
- 5Advisory Committees: Critical to the FDA's Product Review ProcessU.S. Food and Drug Administration · 2018-01-04 · FDA document
The FDA explains that the committee only gives advice, which the FDA does not have to follow, and that the FDA makes the final decision.
- 6Immunogenicity Risk of Peptide Drug Products: Scientific and Regulatory ConsiderationsU.S. Food and Drug Administration · 2024-09-11 · FDA document
How a peptide is made up and given, clumping, and impurities can all change the risk of immune reactions. This is a general rule. Each product still has to be tested on its own.
- 7Clinical Pharmacology Considerations for Peptide Drug ProductsU.S. Food and Drug Administration · 2023-12-01 · FDA document
This is draft advice from the FDA, which drug makers do not have to follow, on developing peptide drugs. It lists questions each product must answer: how the body absorbs and clears it, use in people with liver or kidney problems, drug interactions, effects on heart rhythm, and immune reactions.
- 8Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic ReviewHSS Journal (PubMed record) · 2025-07-31 · Review of many studies
The review is useful as a map of the evidence. It found the research was almost all animal and lab studies, and it did not show that BPC-157 works or is safe in people.